Literature DB >> 25964700

Parathyroid Glands response to Low Vitamin D levels in Healthy Adults: A Cross-Sectional Study.

Mir Sadat-Ali1, Abdullah S Al-Omran1, Haifa A Al-Turki2.   

Abstract

OBJECTIVE: To assess the correlation of serum parathyroid hormone (PTH) and vitamin D (25-OHD) levels based on different assays for measuring 25-OHD in healthy Saudi Arabians living along the east coast. PATIENTS AND METHODS: A cross-sectional study was conducted in 200 patients (150 women and 50 men aged between 18-69 years) between January 2011 and December 2012, attending outpatient clinic at King Fahd Hospital of the University, Al Khobar. The first 200 patients seen without vitamin D supplementation at clinic were enrolled in the study. Serum calcium, phosphorous, alkaline phosphatase, parathormone, and 25-OHD tests were performed. 25-OHD was assessed using:chemiluminescence immunoassay (CLIA)radioimmunoassay (RIA) using Wallac 1470 Gamma CounterHPLC -LC.MS (high performance liquid chromatography-liquid chromatography with mass spectrometry. The data was collected, entered into a database and analysed using SPSS, Inc., version 14.
RESULTS: The mean age was 45.8±15.8 (18-74) years, and calcium level was 2.27±0.15 mmol/l. (range 2.125 to 2.62 mmol/l). Alkaline phosphatase was 88.91±35.94 (34-302) IU, parathormone 6.7±3.06 (1.35-21.2) (1.3-6.8 pmol/l). Of the participants, 188 were either vitamin D insufficient or deficient as measured by CLIA 11.85±6.14 (2-29.6), and 91 (48.4%) of them had secondary hyperparathyroidism 9.48±4.55 pc/l. Those with normal CLIA-measured 25-OHD levels had normal PTH levels. Of those with insufficiency, 4/21 (19%) had raised PTH levels; and of those with deficiency, 81/166 (48.79%) had raised levels, whereas with HPLC-LC.MS, 156 were shown to be insufficient and 97 deficient (with PTH level of 7.41±4.2). Thirteen of 41 patients (31.7%) with insufficiency were shown, by HPLC-LC.MS, to have raised PTH. All patients with vitamin D deficiency as diagnosed by HPLC-LC.MS had secondary hyperparathyroidism.
CONCLUSIONS: The above results suggest that the method of measurement strongly influences vitamin D levels and that previous reports suggesting no association between vitamin D deficiency and secondary hyperparathyroidism should be viewed with caution.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964700      PMCID: PMC4330802     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


INTRODUCTION:

Hyperparathyroidism is a disease entity that occurs due to increased secretion of parathyroid hormone (PTH) from parathyroid glands and causes hypercalcemia.1 Secondary hyperparathyroidism is a response to low calcium levels related to hypovitaminosis D. It is well established that there is an inverse relationship between serum 25-hydroxyvitamin D (25-OHD) and serum PTH.2,3 The levels of 25-OHD that lead to a rise in serum PTH are still a matter of debate.4-6 Reports suggest that not all who are vitamin D insufficient have increased PTH levels.7-9 It has been suggested that the variability of PTH levels in hypovitaminosis D may be due to concomitant magnesium deficiency.[9] Patel et al.10 suggested that glomerular filtration rate is the single most important factor in maintaining PTH levels. Gunnarsson et al.,11 while supporting the kidney function hypothesis, felt that body mass index may play a role in women by blunting the level of PTH and added that in men, insulin-like growth factor 1, smoking, and testosterone levels may do the same. A diagnosis of secondary hyperparathyroidism will therefore depend on measurement of an insufficient or deficient amount of 25-OHD in association with a rise of PTH. The World Health Organization (WHO) described a serum level of 25- OHD of 20 ng/ml or 50 nmol/l as deficiency12 and a level of 30 ng/ml (75 nmol/l) as normal because at this level, PTH drops down to normal levels.13,14 At present, it is believed that below 30 ng/ml of 25-OHD, the level of PTH should start rising.15-16 A review of literature did not reveal any studies correlating PTH levels to the accuracy of 25-OHD levels by different assays; hence, our objective was to determine whether any correlation existed between the true levels of 25-OHD and PTH levels by means of three different assays.

PATIENTS AND METHODS:

A cross-sectional study was conducted in 200 patients (150 women and 50 men) between January 2011 and December 2012, aged between 18-69 years, attending the outpatient clinics at King Fahd Hospital of the University, Al Khobar, Saudi Arabia. The first 200 patients seen who were not taking vitamin D supplementation were included in the study. An earlier study had shown that there was wide variation between the three assays tested. -using a 30 ng/ml cut-off, 6%, 9%, and 22% had normal levels of 25-OHD in CLIA, RIA, and HPLC LC-MS, respectively, and showed different levels of hyperparathyroidism.17 Patients’ weight, height and results of renal and liver function tests were extracted from the medical charts. Serum calcium, phosphorous, alkaline phosphatase, PTH, and 25-OHD tests were performed. 25-OHD was assessed using chemiluminescence immunoassay (CLIA), radioimmunoassay using Wallac 1470 Gamma Counter, and HPLC-LC.MS (high performance liquid chromatography-liquid chromatography with mass spectrometry). The data were analysed using the Statistical Package for the Social Sciences (SPSS), version 14.0, Chicago, Illinois. Data is presented as a mean ± standard deviation (SD). Mean serum 25-hydroxyvitamin D values with 95% confidence intervals (CI) for each assay were calculated, and a p value of <0.05 was considered significant. Each was then compared with parathyroid hormone levels and labelled as normal, insufficient, and deficient in 25-OHD as determined by each assay using linear regression analyses for the relationship between age, sex, CLIA, RIA, HPLC-LS.MS and PTH levels and the correlation between PTH and CLIA, RIA, and HPLC-LS.MC.

RESULTS:

The mean age was 45.8±15.8 (18-74) years, and calcium level was 2.27±0.15 mmol/l. (range 2.125 to 2.62 mmol/l). Alkaline phosphatase was 88.91±35.94 (34-302) IU, PTH 6.7±3.06 (1.35-21.2) (1.3-6.8 pmol/l). Table 1 gives the demographic data of all the patients. Table 2 gives the comparison of 25-OHD between the three assays. Of the participants, 188 were either insufficient or deficient as shown by CLIA 11.85±6.14 (2-29.6), and 91 (48.4%) of them had secondary hyperparathyroidism 9.48±4.55 pc/l, whereas with HPLC-LC. MS, 156 were either insufficient or deficient, 97 with PTH level of 7.41±4.2. In patientswith insufficiency as shown by HPLC-LC-MS, 13/41 (31.7%) had raised parathyroid hormone.
Table I

Demographic characteristics of the patients

VariablesTotal (n=200)
MaleFemale
Sex50 (25)150 (75)
Age (years)48.1±17.0 (14-76)44.8±15.7 (3-80)
Calcium mmol/L2.287±0.212.4±0.065
PO4mg/dl3.7±0.6 (2.6-4.9)4.0±2.9 (1.8-39.0)
Parathromone (pmol/L)7.9±3.5 (3.2-19.8)6.6±4.2 (1.4-43.9)
25-OHD (ng/mL)13.3±7.2 (2.0-34.6)14.0±14.0 (3.3-150.0)
Chemiluminescent immunoassays (ng/mL)9.2±0.7 (8.3-13.1)9.6±6.3 (7.9-86.0)
HPLC-D3 (ng/mL)12.4±4.0 (6.0-25.0)24.7±14.5 (12.0-150.0)

Values are presented as Mean ± SD or n (%); Range in Parenthesis

Table II

25-OHD levels with ≤20 ng/ml as deficiency, 21-29 as insufficiency and normal level as ≥30ng/ml.

Vitamin D LevelsNormalInsufficiencyDeficiency
PTH levelsPTH levelsPTH levels
NormalRaisedNormalRaisedNormalRaised
CLIA1201848086
RIA18062252102
HPLC44013280115
Demographic characteristics of the patients Values are presented as Mean ± SD or n (%); Range in Parenthesis 25-OHD levels with ≤20 ng/ml as deficiency, 21-29 as insufficiency and normal level as ≥30ng/ml. All patients with vitamin D deficiency as diagnosed by HPLC-LC.MS had secondary hyperparathyroidism. Linear regression analyses for the relationship between the age, sex, BMI, creatinine level, and alkaline phosphatase, CLIA, RIA, and LC. MS against PTH levels are given in Table 3. It is clear from Table 3 illustrating linear regression that the beta coefficient of the regression of PTH on RIA is significant at beta=0.160, t=2.341, p<0.05 and HPLC-LC.MS beta=-0.228, t=-3.714, p<0.001 with r square of 0.151, and that there is a significant association between PTH and RIA and HPLC-LC. MS.
Table III

Linear regression analyses for the relationship between the age, sex, BMI, Creatinine level and Alkaline Phosphatase, CLIA, RIA and HPLC-LC.MS against the Parathromone.

Unstandardized CoefficientsR-squareF-valuetP-value
BStd. Error
(Constant)7.9651.7674.509.000
AGE.018.0171.052.294
SEX-.022.699-.031.975
BMI.013.015
Creatinine level.011.0100.1515.551
Alkaline Phosphatase.0110081.361.175
Chemiluminescent immunoassays-.050.050-.995.321
Radioimmunoassay.160.0682.341.020
High-pressure liquid
chromatography-D3-.228.061-3.714.000

Dependent Variable: PARATHROMONE

Linear regression analyses for the relationship between the age, sex, BMI, Creatinine level and Alkaline Phosphatase, CLIA, RIA and HPLC-LC.MS against the Parathromone. Dependent Variable: PARATHROMONE We further performed Pearson correlation analysis, showing the relationship between the variables, and the table depicts that PTH has a significant negative relationship with RIA (r = -0.247, p <0.001), HPLC-LC.MS (r=-0.322, p<0.001) and that RIA has a positively significant relationship with HPLCLC. MS (r=0.946, p<0.001). Hence, there is a significant relationship between PTH and RIA, HPLC-LC.MS (Table 4).
Table IV

Correlation between Parathormone and CLIA, RIA, HPLC-LC.MS.

CLIARIAHPLC
PARATHROMONEr-value-.054-.247-.322
P-value.451.000.000
CLIAr-value1.045.032
P-value.523.654
RIAr-value1.946
P-value.000
HPLCr-value1
P-value
Correlation between Parathormone and CLIA, RIA, HPLC-LC.MS.

DISCUSSION

Our study shows that there is a definite association between hyperparathyroidism and 25-OHD levels, but the assay chosen will influence the level of 25-OHD and hence classification of a patient as vitamin D deficient or insufficient. All patients with normal 25-OHD as assessed by all three assays, CLIA, RIA, and HPLC-LC.MS, had normal PTH levels. In patients with deficiency, PTH was raised in 51.8%, 66.23%, and 100% as assessed by CLIA, RIA, and HPLC-LC.MS, respectively. Our study further supports others which indicate the inverse relationship of 25-OHD and PTH,2,3,18,19 even though Kilicarslan, Cenoliaslan, and Gezgen20 reported that in their study, that over 75% of the vitamin D-deficient patients had normal levels of PTH. In another study of a small number of patients by Elsammak et al.21 PTH did not correlate with serum vitamin D level in either of the genders. Studies have reported different influencing factors that raise PTH level and are not related directly to the level of 25-OHD. Moreover, Vuceljić et al22 found that a raised PTH level is not seen in all patients with 25-OHD deficiency. In their study, only 25.3% with 25-OHD deficiency had raised PTH. On the other hand, Arabi et al23 stated that the negative relationship between 25-OHD and PTH is modulated by age but not gender. Secondly, reports from the Middle Eastern countries indicate that an inverse relationship exists between vitamin D and PTH levels in all age groups.24,25 In this study, we have noticed that the relationship between PTH and 25-OHD existed in all age groups and that gender does play a role. Our male population had significantly higher PTH levels when compared to the female population (7.9±3.5 versus 6.6±4.2 P<0.039), while the 25-OHD level was 13.3±7.2 versus 14.0±14.0 ng/ml (P<0.723), respectively. Ardawi et al26 in their study found that the inverse relationship between 25-OHD and PTH was not influenced by the level of 25-OHD and could not pinpoint the levels of 25-OHD at which PTH levels will plateau. From the studies cited above, it appears that various factors play a role in raising the PTH, but we believe that one important factor that increases PTH is a level of 25-OHD below 20ng/ml. The inconsistency of other reports of the relationship of PTH and 25-OHD may be due to the inaccuracy of the assay used in the assessment. Our study has limitations as a small cohort group, and differences in the gender comparison were unequal; secondly, we also need to compare results from different PTH assays, as well. The strength of our study is that we have tried for the first time to check the vitamin D levels with three different assays and simultaneously correlate PTH levels with different assays. The results of this study, we believe, should give a direction for future studies to correlate PTH levels with 25- OHD with a properly calibrated assay. In conclusion, we found that serum PTH levels are normal with all 25-OHD assays of ≥30ng/ml, while issues lie in the accurate measurement of insufficiency and deficiency of 25-OHD. With HPLC-LC.MS, the gold standard to assess 25-OHD, all deficient patients had a raised PTH, while other assays showed normal PTH.
  22 in total

1.  Glomerular filtration rate is a major determinant of the relationship between 25-hydroxyvitamin D and parathyroid hormone.

Authors:  S Patel; S Hyer; J Barron
Journal:  Calcif Tissue Int       Date:  2007-04-13       Impact factor: 4.333

Review 2.  Vitamin D status and its relationship with parathyroid hormone and bone mineral status in older adolescents.

Authors:  Alexis M Willett
Journal:  Proc Nutr Soc       Date:  2005-05       Impact factor: 6.297

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women.

Authors:  Hussein F Saadi; Nicolaas Nagelkerke; Sheela Benedict; Hussein S Qazaq; Erica Zilahi; Mohammad K Mohamadiyeh; Abdulrahim I Al-Suhaili
Journal:  Bone       Date:  2006-06-30       Impact factor: 4.398

5.  Prevalence of vitamin D insufficiency in an adult normal population.

Authors:  M C Chapuy; P Preziosi; M Maamer; S Arnaud; P Galan; S Hercberg; P J Meunier
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

6.  Estimates of optimal vitamin D status.

Authors:  Bess Dawson-Hughes; Robert P Heaney; Michael F Holick; Paul Lips; Pierre J Meunier; Reinhold Vieth
Journal:  Osteoporos Int       Date:  2005-03-18       Impact factor: 4.507

7.  Hypovitaminosis D and 'functional hypoparathyroidism'-the NoNoF (Nottingham Neck of Femur) study.

Authors:  O Sahota; K Gaynor; R H Harwood; D J Hosking
Journal:  Age Ageing       Date:  2001-11       Impact factor: 10.668

8.  Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency.

Authors:  O Sahota; M K Mundey; P San; I M Godber; D J Hosking
Journal:  Osteoporos Int       Date:  2006-04-05       Impact factor: 4.507

9.  Association between vitamin D and bone mineral density in Iranian postmenopausal women.

Authors:  Farhad Hosseinpanah; Mehdi Rambod; Arash Hossein-nejad; Bagher Larijani; Fereidoun Azizi
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

10.  Assessment of low vitamin D among Saudi Arabians. Did we overshoot the runway?

Authors:  Mir Sadat-Ali; Abdulmohsen H Al-Elq; Iman H Al-Shaikh; Haifa A Al-Turki; Amein K Al-Ali; Abdallah A Al-Othman
Journal:  Saudi Med J       Date:  2014-10       Impact factor: 1.484

View more
  3 in total

1.  Parathyroid Gland Response to Vitamin D Deficiency in Type 2 Diabetes Mellitus: An Observational Study.

Authors:  Azhar Hussain; Omar B Latiwesh; Alia Ali; Elsa Tabrez; Lalit Mehra; Fidelis Nwachukwu
Journal:  Cureus       Date:  2018-11-28

2.  Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO).

Authors:  Nasser M Al-Daghri; Yousef Al-Saleh; Naji Aljohani; Riad Sulimani; Abdulaziz M Al-Othman; Hanan Alfawaz; Mona Fouda; Fahad Al-Amri; Awad Shahrani; Mohammed Alharbi; Fahad Alshahrani; Waleed Tamimi; Shaun Sabico; Rene Rizzoli; Jean-Yves Reginster
Journal:  Arch Osteoporos       Date:  2016-12-21       Impact factor: 2.617

3.  Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course.

Authors:  Jarred Strickling; Michael J Wilkowski
Journal:  Case Rep Nephrol Dial       Date:  2019-04-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.